Eurolife snaps up Baxter’s form-fill-seal unit in India for undisclosed price

Eurolife Healthcare, a specialty drugmaker based in India, picked up the form-fill-seal infusion products unit of U.S.-based Baxter International for an undisclosed price.

The deal consolidates Eurolife’s position as a major player in the form-fill-sealed segment, BW Businessworld reported. The technology is used in sterile manufacturing of liquid drugs and intravenous fluids.

Under the terms of the acquisition, Eurolife gets the products and technology as well as Baxter’s facilities in India. 


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

It’s expected the sale will be closed by the end of the year.

“Eurolife is totally committed to making significant investments in the acquired facilities, in order to expand capacity to feed our flourishing FFS infusions business both locally and globally,” Sandeep Toshniwal, Eurolife’s CEO, said in a statement.

Eurolife, based in Mumbai, was founded in 2001. With the Baxter agreement under its belt it will have manufacturing facilities in Maharashtra, Tamil Nadu and Uttarakhand. The company currently markets to 22 countries in Asia, the Pacific region and Latin America.

Suggested Articles

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.

Just months after a C-suite shakeup at Amneal, the generics company has struck a $220 million deal for AvKare, known on the street as R&S Northeast. 

Fujifilm has completed the first manufacturing facility in Japan to make drug-delivering liposomes to use for cancer fighting drugs it is developing.